Atlas Trials

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

Clinical trial NCT03586297 · COMPLETED

Trial details

NCT number
NCT03586297
Sponsor
Hackensack Meridian Health
Status
COMPLETED
Study type
OBSERVATIONAL
Triple Negative Breast Cancer
Start date
2017-08-27
Primary completion
2025-09-15
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.